These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 10687988)
1. Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. Weitzman AL; Shelton G; Zuech N; Owen CE; Judge T; Benson M; Sawczuk I; Katz A; Olsson CA; Bagiella E; Pfaff C; Newhouse JH; Petrylak DP J Urol; 2000 Mar; 163(3):834-7. PubMed ID: 10687988 [TBL] [Abstract][Full Text] [Related]
2. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer. Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757 [TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer. Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348 [TBL] [Abstract][Full Text] [Related]
4. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy. Hirano D; Minei S; Kishimoto Y; Yamaguchi K; Hachiya T; Yoshida T; Yoshikawa T; Endoh M; Yamanaka Y; Yamamoto T; Satoh Y; Ishida H; Okada K; Takimoto Y Urol Int; 2005; 75(1):43-9. PubMed ID: 16037707 [TBL] [Abstract][Full Text] [Related]
5. Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Hainsworth JD; Meluch AA; Spigel DR; Yost K; Meng C; Greco FA Clin Genitourin Cancer; 2006 Mar; 4(4):287-92. PubMed ID: 16729913 [TBL] [Abstract][Full Text] [Related]
6. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Sinibaldi VJ; Carducci MA; Moore-Cooper S; Laufer M; Zahurak M; Eisenberger MA Cancer; 2002 Mar; 94(5):1457-65. PubMed ID: 11920502 [TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer. Hussain M; Smith DC; El-Rayes BF; Du W; Vaishampayan U; Fontana J; Sakr W; Wood D Urology; 2003 Apr; 61(4):774-80. PubMed ID: 12670564 [TBL] [Abstract][Full Text] [Related]
11. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer. Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587 [TBL] [Abstract][Full Text] [Related]
13. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer. Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643 [TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer. Safarinejad MR Urol Oncol; 2005; 23(2):93-101. PubMed ID: 15869993 [TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer. Sella A; Sternberg CN; Skoneczna I; Kovel S BJU Int; 2008 Dec; 102(11):1607-9. PubMed ID: 18990177 [TBL] [Abstract][Full Text] [Related]
16. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. Petrylak DP; Macarthur RB; O'Connor J; Shelton G; Judge T; Balog J; Pfaff C; Bagiella E; Heitjan D; Fine R; Zuech N; Sawczuk I; Benson M; Olsson CA J Clin Oncol; 1999 Mar; 17(3):958-67. PubMed ID: 10071290 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer. Matsumoto A; Inoue A; Yokoi S; Nozumi K; Miyazaki K; Hosoki S; Nagata M; Yamaguchi K Int J Urol; 2009 Aug; 16(8):687-91. PubMed ID: 19602005 [TBL] [Abstract][Full Text] [Related]
18. Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer. Sinibaldi VJ; Carducci M; Laufer M; Eisenberger M Semin Oncol; 1999 Oct; 26(5 Suppl 17):45-8. PubMed ID: 10604269 [TBL] [Abstract][Full Text] [Related]
19. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study. Tiffany NM; Ryan CW; Garzotto M; Wersinger EM; Beer TM J Urol; 2005 Sep; 174(3):888-92. PubMed ID: 16093981 [TBL] [Abstract][Full Text] [Related]
20. Phase II study of low-dose docetaxel/estramustine in elderly patients or patients aged 18-74 years with hormone-refractory prostate cancer. Chittoor S; Berry W; Loesch D; Logie K; Fleagle J; Mull S; Boehm KA; Zhan F; Asmar L Clin Genitourin Cancer; 2006 Dec; 5(3):212-8. PubMed ID: 17239275 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]